Clinical data
Other names
ETH-LAD, 6-ethyl-6-nor-Lysergic acid diethylamide
Legal status
Pharmacokinetic data
Hepatic
Renal
Identifiers
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-
hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
C21H27N3O
337.467 g·mol−1
3D model (JSmol)
CCN(C([C@@H]1C=C2C3=CC=CC4=C3C(C[C@H]2N(CC)C1)=CN4)=O)CC
InChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1 Y
Key:MYNOUXJLOHVSMQ-DNVCBOLYSA-N Y
ETH-LAD, 6-ethyl-6-nor-lysergic acid diethylamide is an analogue of LSD. Its human psychopharmacology was first described by Alexander Shulgin in the book TiHKAL. ETH-LAD is a psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[2] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding. The true tryptamine counterpart of ETH-LAD is MET, a simplified version of this structure.
On June 10, 2014, the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[3] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[4]
ETH-LAD is illegal in Switzerland as of December 2015.[5]
Psychedelics
(5-HT2A
agonists)
25x-NB3OMe
25x-NB4OMe
25x-NBF
25x-NBMD
25x-NBOH
25x-NBOMe
Atypical structures
25x-NMx
3C-x
4C-x
HOT-x
Mescaline (subst.)
Others
x-DALT
x-DET
x-DiPT
x-DMT
x-DPT
Ibogaine-related
x-MET
x-MiPT
Others
Others
PCP-related
Others
Diarylethylamines
Others
Others
GABAA
enhancers
Others
Lysergic acid
derivatives
Clavines
Other
ergolines
Natural
sources
Morning glory: Argyreia nervosa (Hawaiian Baby Woodrose), Ipomoea spp.(Morning Glory, Tlitliltzin, Badoh Negro), Rivea corymbosa (Coaxihuitl, Ololiúqui)